TY - JOUR
T1 - Intranasal application of xenon reduces opioid requirement and postoperative pain in patients undergoing major abdominal surgery
T2 - A randomized controlled trial
AU - Holsträter, Thorsten Frederik
AU - Georgieff, Michael
AU - Föhr, Karl Josef
AU - Klingler, Werner
AU - Uhl, Miriam Elisabeth
AU - Walker, Tobias
AU - Köster, Sarah
AU - Grön, Georg
AU - Adolph, Oliver
PY - 2011/8
Y1 - 2011/8
N2 - Background: Both central sensitization after peripheral tissue injury and the development of opioid tolerance involve activation of N-methyl-d-aspartate (NMDA) receptors. At subanesthetic doses the NMDA receptor antagonist xenon suppresses pain-evoked sensitization of pain-processing areas in the central nervous system. Although numerous studies describe the effect of NMDA receptor antagonists on postoperative pain, clinical studies elucidating their intraoperative analgesic potency when applied in a low dosage are still largely missing. Methods: To analyze the analgesic effect of low-dose xenon using new application Methods, the authors tested nasally applied xenon as an add-on treatment for analgesia in 40 patients undergoing abdominal hysterectomy. Within a randomized double-blind placebo-controlled study design, intraoperative and postoperative requirement of opioids as well as postoperative subjective experiences of pain were measured as primary outcome variables. Results: Intranasal application of xenon significantly reduced intraoperative opioid requirement (mean difference [MD] -2.0 μg/min; 95% CI [CI95]-0.53 to -3.51, Bonferroni correction adjusted P value [pcorr]= 0.028) without relevant side effects and significantly reduced postoperative pain (MD -1.34 points on an 11-point rating scale; CI95 -0.60 to -2.09, p corr = 0.002). However, postoperative morphine consumption (MD -8.8 μg/min; CI95 1.2 to -18.8, pcorr = 0.24) was not significantly reduced in this study. Conclusions: Low-dose xenon significantly reduces intraoperative analgesic use and postoperative pain perception. Because NMDA receptor antagonists suppress central sensitization, prevent the development of opioid tolerance, and reduce postoperative pain, the intraoperative usage of NMDA receptor antagonists such as xenon is suggested to improve effectiveness of pain management within a concept of multimodal analgesia.
AB - Background: Both central sensitization after peripheral tissue injury and the development of opioid tolerance involve activation of N-methyl-d-aspartate (NMDA) receptors. At subanesthetic doses the NMDA receptor antagonist xenon suppresses pain-evoked sensitization of pain-processing areas in the central nervous system. Although numerous studies describe the effect of NMDA receptor antagonists on postoperative pain, clinical studies elucidating their intraoperative analgesic potency when applied in a low dosage are still largely missing. Methods: To analyze the analgesic effect of low-dose xenon using new application Methods, the authors tested nasally applied xenon as an add-on treatment for analgesia in 40 patients undergoing abdominal hysterectomy. Within a randomized double-blind placebo-controlled study design, intraoperative and postoperative requirement of opioids as well as postoperative subjective experiences of pain were measured as primary outcome variables. Results: Intranasal application of xenon significantly reduced intraoperative opioid requirement (mean difference [MD] -2.0 μg/min; 95% CI [CI95]-0.53 to -3.51, Bonferroni correction adjusted P value [pcorr]= 0.028) without relevant side effects and significantly reduced postoperative pain (MD -1.34 points on an 11-point rating scale; CI95 -0.60 to -2.09, p corr = 0.002). However, postoperative morphine consumption (MD -8.8 μg/min; CI95 1.2 to -18.8, pcorr = 0.24) was not significantly reduced in this study. Conclusions: Low-dose xenon significantly reduces intraoperative analgesic use and postoperative pain perception. Because NMDA receptor antagonists suppress central sensitization, prevent the development of opioid tolerance, and reduce postoperative pain, the intraoperative usage of NMDA receptor antagonists such as xenon is suggested to improve effectiveness of pain management within a concept of multimodal analgesia.
UR - http://www.scopus.com/inward/record.url?scp=79961025162&partnerID=8YFLogxK
U2 - 10.1097/ALN.0b013e318225cee5
DO - 10.1097/ALN.0b013e318225cee5
M3 - Article
AN - SCOPUS:79961025162
SN - 0003-3022
VL - 115
SP - 398
EP - 407
JO - Anesthesiology
JF - Anesthesiology
IS - 2
ER -